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 Centre de Neuroscience Paris Sud – CNPS – Université Paris Sud XI 
France 
1. Introduction 
1.1 History and definition of viral vectors 
Viruses are intracellular parasites with simple DNA or RNA genomes (Figure 1A). Three 
steps compose virus life cycle: infection of a host cell, replication of its genome within the 
host cell environment, and formation of new virions (Figure 1B). This process is often but 
 
Fig. 1. Virus. (A) Structure. Simplified scheme of virus structure, with a lipid envelope that 
can be present or not; a protein-composed capsid and the genetic material, that can be DNA 
or RNA, double or single strand. (B) Life cycle. Example of the course of adeno-associated 
virus (AAV) productive infection. Scheme showing the eight steps of AAV transduction of 
host cells: (1) viral binding to a membrane receptor/co-receptor; (2) endocytosis of the virus 
by the host cell; (3) virus intracellular trafficking through the endosomal compartment; (4) 
escape of the virus from the endosome; (5) virion uncoating; (6) entry into the nucleus; (7) 
viral genome conversion from a single-stranded to a double-stranded genome; and (8) 
integration into the host genome or permanence of an episomal form capable of expressing 
an encoded gene (from Coura and Nardi, 2008). 
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not always associated with pathogenic effects against the host organism. Nevertheless, since 
the mid-1980s, a likely useful role for virus has been envisaged. The idea is to use the unique 
virus capacity to enter the cell and to replicate their genome to construct vectors, containing 
the viral envelope and a recombinant genome, so that these vectors could be able to deliver 
genetic material into cells. Then, recombinant viral vectors are created in which genes 
essential for viral replication are removed and a gene of interest is inserted in the viral 
genome (Figure 2). While this eliminates pathogenicity due to viral replication, retention of 
viral genes and continued expression of these genes may limit the potential of the current 
generation of vectors. Meanwhile, defective viral vectors represent a different approach, in 
which only viral recognition signals are used to allow packaging of foreign DNA into a viral 
coat while eliminating the possibility of viral gene expression (see glossary) within target 
cells. These viral vectors would be able to long-term gene delivery to mammalian cells, 
without pathogenicity and with minimal associated toxicity. Today, several viral vector 
systems are close to achieving this aim, providing stable transgenic expression in many 
different cell types and tissues. 
1.2 Viral vectors 
For the production of an efficacious and safe viral vector it is required at first to identify 
the crucial viral sequences for viral particle assembly, for viral genome package, and for 
transgene (see glossary) delivery to target cells. Then, dispensable genes are deleted from 
viral genome in order to reduce its pathogenicity and immunogenicity. At last, residual 
viral genome and transgene are integrated into the construct (Figure 2). Some viral vectors 
are able to integrate host genome unlike others that remain in an episomal form. 
Integrative vectors, like retroviruses and adeno-associated vectors are able to promote a 
persistent transgene expression. Otherwise, non-integrative vectors, like adenovirus 
whose viral DNA is maintained in an episomal form into infected cells, lead to a transient 
transgene expression. Each vector presents specific advantages and limitations that 
become more or less proper depending on the objective of its application 
(http://cmbi.bjmu.edu.cn/cmbidata/therapy/research/re02/021.htm; Osten et al., 2007; 
Howarth et al., 2010). 
The ideal vector has not been described yet, but its characteristics should include: 
 Easy and efficient production of high titers of viral particle; 
 Absence of toxicity to target cells and undesirable effects like as immune response 
against the vector or the transgene;  
 Capacity of site-specific integration, allowing a long-term transgene expression, as in 
cases of genetic disorders;  
 Capacity of transduction of specific cell types;  
 Infection of proliferative and quiescent cells. 
Most vectors used for gene delivery are derived from human viral pathogens that have been 
made nonpathogenic by deleting essential viral genes. They usually have a broad tropism; 
therefore they can infect and deliver their encoded transgenes to a wide spectrum of cells 
and/or tissues. 
Currently, the most efficient and commonly used viral vectors are adenovirus (Ad), adeno-
associated virus (AAV), herpes simplex virus type 1-derived vectors (HSV-1), and 
retrovirus/lentivirus vectors (Table 1). 
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Fig. 2. Example of vector construction. (A) Wild AAV. (B) AAV recombinant vector 
production. AAV vector cassette, containing only the ITRs of the wild virus and the 
transgene and its promoter; helper cassette, containing the AAV rep and cap genes required 
for virus packaging and the Ad genes E2, VA and E4, required for virus replication. (1); co-
transfection of both plasmids in HEK 293 packaging cells, whose genome contains the Ad E1 
gene, which together with the other Ad required genes, supplied by the helper plasmid, 
allows the establishment of a productive infection (2); empty capsid is formed by AAV 
structural proteins assembly into the nucleolus (3); the replicated ssDNA viral genome with 
the transgene flanked by ITRs (vector plasmid) are packaged into the empty capsid in the 
nucleoplasm (4), giving rise to a non-replicative recombinant AAV vector virion (5). The 
regulatory proteins act especially in the replication and packaging processes (from Coura 
and Nardi, 2008). 
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Virus vector Description Advantages Limitations Applications 
Adenovirus  
(Ad) 
 Icosahedric 
 Non- enveloped 
 Genome capacity of 36 
Kb 
 Entry into the cell by 
receptor binding 
 Episomal (non-
integrative) 
 Capable of 
transducing 
postmitotic cells 
 Persistence of 
expression for weeks 
or months 
 Difficult production 
 Toxicity 
 Easy propagation 
in high titers(1010-
1013); 
 High transduction 
efficiency; 
 Infection of the  
majority of cell 
types; 
 Possibility of 
insertion of large 
DNA fragments 
(up to 8kb); 
 Infects both 
replicating and 
differentiated 
cells. 
 High 
immunogenicity, 
inducing an 
important cellular 
and humoral 
immune response 
that can be fatal; 
 Transient 
expression 
 Viral proteins can 
be expressed in host 
following vector 
administration 
Therapies that 
require transient 
gene expression: 
cancer therapy, 
angiogenesis 
induction and 
DNA vaccine 
production (due 
to its 
inflammatory 
and 
immunogenic 
properties); 
Retrovirus 
(Retrovirus 
and 
Lentivirus) 
 Globular 
 Enveloped 
 Genome capacity of 8 
Kb 
 Entry into the cell by 
fusion 
 Integrative 
 Capable of 
transducing 
proliferative 
(retrovirus and 
lentivirus) and 
quiescent (lentivirus) 
cells 
 Persistence of 
expression for years 
 Easy production 
 Minimal toxicity 
 Low 
immunogenicity; 
 Possibility of 
insertion of 
modest  DNA 
fragments (up to 8 
Kb); 
 High transduction 
efficiency; 
 Integrates into 
host genome 
resulting in 
sustained 
expression of 
vector 
 Extremely well 
studied system 
 Vector proteins 
not expressed in 
host 
 Insertional 
mutagenesis 
(random 
integration) 
 Low titers (106- 107)
 In vivo delivery 
remains poor. 
Effective only when 
infecting helper cell 
lines 
 
 Genetic 
diseases of T 
cells and 
hematological 
diseases 
(Retrovirus); 
 HIV/AIDS 
 Optogenetics 
 Neuronal 
tracing 
Adeno-
associated 
virus 
(AAV) 
 Icosahedric 
 Non- enveloped 
  Genome capacity of 
4.7 Kb 
 Entry into the cell by 
receptor binding 
 Integrative 
 Capable of 
transducing 
postmitotic cells 
 Persistence of 
expression for years 
 Difficult production 
 No toxicity 
 Low 
immunogenicity; 
 Easy propagation 
in high titers; 
 Infection of the  
majority of cell 
types; 
 Long-term gene 
expression 
Limited capacity for 
DNA fragments 
insertion 
  Genetic 
Diseases 
 Tumors 
 Neurological 
Diseases 
 Ocular 
Diseases 
 Cardiovascular 
Diseases  
 Others 
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Herpes 
Simplex 
Virus (HSV) 
 Icosahedric 
 Enveloped 
 Genome capacity of 30 
Kb 
 Entry into the cell by 
fusion 
 Episomal (non-
integrative) 
 Capable of 
transducing 
postmitotic cells 
 Persistence of 
expression for weeks  
 Difficult production 
 Toxicity 
 Large insert size 
 Could provide 
long- term CNS 
gene expression 
 High titer 
 System currently 
under development
 Current vectors 
provide transient 
expression 
 Low transduction 
efficiency 
 Toxicity 
 
  Neuronal 
gene transfer, 
in vitro and in 
vivo. 
 
Table 1. Main viral vectors systems and their characteristics. 
1.2.1 Adenovirus 
Adenoviruses (Ads) are medium-sized (90–100 nm), non-enveloped icosahedral viruses 
composed of a nucleocapsid and a double-stranded linear DNA genome. The viral genome 
is large, consisting of a single double-stranded DNA molecule 36 to 38 kilobases in size. 
Viral DNA replication and transcription are complexes, and viral replication and assembly 
occur only in the nucleus of infected cells. Mature virions are released by cellular 
disintegration. 
There are 55 described serotypes in humans, which are responsible for 5–10% of upper 
respiratory infections in children, and many infections in adults as well. 
Adenoviral infection is initiated by the virus binding to the cellular receptor. Internalization 
occurs via receptor-mediated endocytosis followed by release from the endosome. After 
endosomal release, the viral capsid undergoes disassembly while moving to the nuclear 
pore. Nuclear entry of the viral DNA is completed upon capsid dissociation, and the viral 
DNA does not integrate into the host genome but remains in an episomal state. 
Since adenoviral replication depends on the E1A region of the viral genome, all recombinant 
adenoviral vectors have this region of its genome deleted, and are referred to as "replication-
deficient" virus. Such vectors are capable of infecting a cell only once, no viral propagation 
occurs, and the infected cell does not die as a result of vector infection. As replication-
deficient viruses are required, the 293 cell line is utilized for vector production. This is a 
human kidney cell line which has been stably transfected with the E1A region of the 
adenoviral genome. This allows the vector to be made and matured within the 293 cell, yet 
vectors prepared from this cell line will lack the E1A region and remain replication-
deficient.  
The non-integrative feature of adenovirus limits their use in basic research, although 
adenoviral vectors are occasionally used in in vitro experiments. Their primary applications 
are in gene therapy, especially oncolytic gene therapy, and vaccination (Ayuso et al., 2010). 
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1.2.2 Retrovirus 
Retroviruses are globular enveloped virions ranging in diameter from 80 to 130 nm. The 
viral genome is encased within the capsid along with the proteins integrase and reverse 
transcriptase. The genome consists of two identical positive (sense) single-stranded RNA 
molecules ranging in size from 3.5 to 10 kilobases. Following cellular entry, the reverse 
transcriptase synthesizes viral DNA using the viral RNA as its template. The cellular 
machinery then synthesizes the complementary DNA which is then circularized and 
inserted into the host genome. Following insertion, the viral genome is transcribed and viral 
replication is completed. The majority of retroviruses are oncogenic although the degree to 
which they cause tumors varies from class to class. 
As the inserted vector, called a provirus, remains in the genome, it passes on to the progeny 
of the cell when it divides. However, the site of integration is unpredictable, what can 
represent an obstacle in using of these vectors. The provirus can disturb the function of 
cellular genes and lead to activation of oncogenes promoting the development of cancer 
(insertional mutagenesis), which raises concerns for possible applications in gene therapy.  
Retroviral vectors can either be replication-competent or replication-defective, even if 
replication-defective vectors are the most common choice. Replication-competent viral 
vectors contain all necessary genes for virion synthesis, and continue to propagate 
themselves once infection occurs. Because the viral genome for these vectors is much 
lengthier, the length of the actual inserted gene of interest is limited compared to the 
possible length of the insert for replication-defective vectors.  
In addition to insertional mutagenesis, the primary drawback to use of retroviruses, such as 
the Moloney retrovirus, involves the requirement for cells to be actively dividing for 
transduction. As a result, cells such as neurons are very resistant to infection and 
transduction by retroviruses.  
Lentiviruses are a subclass of Retroviruses. They have been adapted as gene delivery 
vehicles thanks to their ability to integrate into the genome of non-dividing cells, which is a 
unique feature of Lentiviruses as other Retroviruses can infect only dividing cells. 
Moreover, studies have shown that lentivirus vectors have a lower tendency to integrate in 
places that potentially cause cancer than other retroviral vectors. 
For safety reasons lentiviral vectors never carry the genes required for their replication. To 
produce a lentivirus, several plasmids are transfected into a so-called packaging cell line, 
commonly HEK 293. One or more plasmids, generally referred to as packaging plasmids, 
encode the virion proteins, such as the capsid and the reverse transcriptase. Another 
plasmid contains the genetic material to be delivered by the vector. It is transcribed to 
produce the single-stranded RNA viral genome and is marked by the presence of the ψ (psi) 
sequence. This sequence is used to package the genome into the virion (Mátrai et al., 2010; 
Kumar & Woon-Khiong, 2011; Yi et al., 2011). 
1.2.3 Adeno-associated virus 
Adeno-associated viruses (AAV) belongs to the genus Dependovirus and family 
Parvoviridae. It is currently not known to cause disease. The Parvoviridae family is 
characterized by small, ichosaedral and non-enveloped virus whose genome is a single 
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stranded DNA. AAV is one of the smallest viruses with a capsid of approximately 22 nm 
and one of the most spread of this family, leading to seropositivity in more than 80% of 
human population (serotype 2). Despite this high seroprevalence, the virus has not been 
linked to any human illness, causing a very mild immune response. Because a co-infecting 
helper virus is usually required for a productive infection to occur, AAV serotypes are 
ascribed to a separate genus in the Parvoviridae family designated Dependovirus. 
The wild AAV has a linear single-stranded DNA genome of approximately 4.7 Kb of either 
plus (sense) or minus (anti-sense) polarity. The AAV2 DNA termini consist of a 145 
nucleotide-long inverted terminal repeat (ITR) that forms a characteristic T-shaped hairpin 
structure. These ITRs are important in the site-specific integration of AAV DNA into a 
specific site in chromosome 19. The ability of wild-type AAV to selectively integrate into 
chromosome 19 made them an attractive candidate for the production of a gene therapy 
vector that could do the same. The ITRs act as DNA replication origin, as well as signal for 
package and integration. In addition, they also act as regulator element for wild AAV gene 
expression. The ITRs flank the two viral genes rep (replication) and cap (capsid) encoding 
nonstructural and structural proteins, respectively. The virus does not encode a polymerase 
relying instead on cellular polymerase activity to replicate its DNA (Ni et al., 1998).  
Adeno-associated vectors are prepared by replacing the capsid genes with the gene of 
interest. Construction of AAV vectors consists of the recombinant AAV vector plasmid 
DNA, and a non-rescuable AAV helper plasmid, which encodes for the AAV capsid 
proteins. Also required is either wild-type adenovirus or HSV and cell line for viral 
propagation. Unlike the previous vector systems described, the cell line need not contain 
any portion of the AAV genome since all required AAV genome elements could be 
provided by the two plasmids. Cells are first infected with the wild-type adenovirus or 
HSV, and then both the recombinant AAV vector plasmid DNA and the non-rescuable AAV 
helper plasmid are co-transfected into the cells. The cells produce mature recombinant AAV 
vectors as well as wild-type adenovirus or HSV. The wild-type adenovirus or HSV is 
removed by either density gradient centrifugation or heat inactivation. 
These vectors have been designed to produce a gene therapy vector with site-specific 
integration and the ability to infect multiple cell types. Unfortunately, this has not been the 
case to date for these vectors. Current research focuses on how to regain the site-specific 
integration sequences into the recombinant vector. These vectors do offer some advantages 
over other vector systems which include the lack of initiating an immune response, their 
stability and ability to infect a variety of dividing and non-dividing cells. Unfortunately, 
they cannot incorporate genes larger than 5 kb and must be closely screened for adenoviral 
or HSV contamination (Berns, 1996; Grimm & Kay, 2003; Coura & Nardi, 2007; Coura & 
Nardi, 2008; Mezzina & Merten, 2011). 
1.2.4 Herpes simplex virus 
Herpes simplex viruses are members of the herpes virus family, Herpesviridae, that infect 
humans. They are ubiquitous neurotropic and neuroinvasive viruses that persist in the body 
by becoming latent and hiding from the immune system in the cell bodies of nerves. Latency is 
defined as a state in which viral DNA is maintained within the cell nucleus in the absence of 
any viral replication. The structure of herpes viruses consists of a relatively large double-
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stranded, linear DNA genome encased within an icosahedral capsid, which is wrapped in a 
lipid bilayer envelope. The HSV genome has been entirely sequenced and is rather extensively 
studied. As a result, currently, a general knowledge exists of which genes and DNA sequences 
may be deleted and at which sites foreign DNA may be inserted into the viral genome. These 
studies also have defined the minimal requirements for viral replication and packaging. 
Vectors derived from Herpes simplex virus (HSV) have some unique features. The vectors 
have a wide host range and cell tropism, infecting almost every cell type in most vertebrates. 
In addition, the natural property of the virus to infect and establish latent infection 
indefinitely in post-mitotic neurons has generated substantial interest in using it to deliver 
therapeutic genes to the nervous system. 
The two main strategies for HSV-based vectors in use today are genetically-engineered 
viruses and plasmid derived "amplicon" vectors. The first strategy involves the construction 
of recombinant viruses containing deletions in one or more viral genes whose expression is 
essential for viral replication, resulting in replication-incompetent vectors.  
The second strategy involves the use of plasmid-derived vectors containing HSV-1 origins of 
DNA replication and DNA packaging signals that enable multiple copies of the vector 
genomes to be packaged into helper virus virions. Helper viruses can be either recombinant 
viruses containing a deletion within an essential viral gene or viruses containing temperature-
sensitive mutations that prevent replication at 37° C (normal body temperature). In the case of 
the former, the replication of the helper virus and packaging of the amplicon vector DNA must 
occur in a cell line capable of complementing the mutations in the helper virus.  
Regardless of the vector system used, two primary goals must be achieved to enable long-
term gene expression in neuronal cells. The first goal involves the construct of mutant 
vectors which themselves are noncytotoxic to cells. Several studies have noted active 
expression of a foreign gene by HSV vector constructs, which subsequently became 
inactivated. Reasons for this are not completely apparent, but evidence suggests that the 
inactivation is a result of cytotoxic effects induced by vector systems. 
The second goal involves designing stable, active promoters capable of expressing appropriate 
levels of the foreign protein. The specific promoter involved in individual therapies may 
change according to the type, status and activity of the neuronal cell of interest.  
Currently, many studies have demonstrated long-term stable transgene expression in the 
nervous system. In addition, preclinical studies on models of neurological disease, such as 
glioma, peripheral neuropathy, chronic pain and neurodegeneration, show encouraging 
results (Jenkins & Turner, 1996; de Silva & Bowers, 2009; Glorioso & Fink, 2009; Manservigi 
et al., 2010; Fraefel et al., 2011; Goins et al., 2011).    
1.3 Viral vectors in neurobiology 
Gene transfer into the central nervous system (CNS) shows great promise for basic and 
clinical research in neurosciences. As the brain presents a high level of structural 
complexity, it is a complicated target to be accessed and for genetic manipulation.  
Currently, viruses are the most widely used vehicles for gene transfer into the adult 
mammalian brain.  However, there does not exist a “universal ideal vector” and each basic 
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or clinical approach may require a specific set of technical hurdles to overcome. Several viral 
vectors have been studied. Each one has shown great advantages and disadvantages 
depending basically on the subset of target cells and the specificities of each research or 
clinical indication.  
The number of suitable vectors for basic research surpasses those being used in clinical 
trials. Currently, the most widely used vectors in neurobiology are AAV, HSV and lentiviral 
vectors. AAV presents several serotypes with specific cell tropism. AAV serotype 2 (AAV2), 
for example, infects neurons preferentially, but seems to not infect all types of neurons 
equally well. Other serotypes, as AAV4 and AAV5, show distinct tropism and diffusion 
properties. The construction of vectors combining more than one serotype and using specific 
cell promoters, allows genetic manipulation of specific sets of neurons, with more sustained 
and effective transgene delivery and expression. AAV vectors are highly effective for gene 
delivery and are non-toxic. The main limitation of these vectors is its relatively small gene 
capacity (McCown, 2011).  
HSV is neurotrophic and shows a highly efficient retrograde and anterograde transport 
within the CNS, being able of entering in a benign latent state. HSV vectors have a large 
transgene capacity and can assure long-lasting transgene expression. However, the main 
disadvantage of this type of vector is its cell toxicity and low transduction efficiency.  
Currently, other variants that try to surpass these limitations have been developed. 
Lentivirus vectors have a modest packaging capacity, induce minimal immunological 
response and can produce long-term transgene expression. In addition, envelope-
engineered vectors can show broad cell tropism. On the other hand, these vectors show poor 
in vivo delivery and present the risk of insertional mutagenesis. However, as lentiviruses 
mostly transduce terminally differentiated cells, the risk of insertional mutagenesis is less 
important than observed for other retroviruses (Kaplitt & Pfaff, 1996; Davidson & 
Breakefield, 2003; Howarth et al., 2010; Snyder et al., 2010).  
2. Therapeutic and research applications 
Viral vectors were originally developed as an alternative to transfection (see glossary) of 
naked DNA for molecular genetics experiments. Compared to traditional methods such as 
calcium phosphate precipitation, transduction (see glossary) can ensure that nearly 100% of 
cells are infected without severely affecting cell viability. Furthermore, some viruses 
integrate into the cell genome facilitating stable expression. 
Protein coding genes can be expressed using viral vectors, commonly to: 
1. Increase concentration of a certain protein and study its function (over-expression 
studies); 
2. Antagonize function of a certain protein (expression of dominant negative proteins and 
RNAi constructs); 
3. Make the cell produce fluorescent indicator proteins (for example, EGFP or Ca2+ 
sensitive proteins). These may be used to monitor various variables within the living 
cells (tracing and in vivo imaging); 
4. Control neuronal excitability using light-sensitive ion channels (optogenetics); 
5. Pre-clinical and clinical gene therapy approaches. 
Therefore, viral vectors constitute an important tool and present extraordinary opportunities 
for basic and clinical research, particularly in neurosciences. 
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2.1 Gene expression in vitro and in vivo 
Viral vectors have emerged as an important tool for manipulating gene expression in the 
adult mammalian brain. The adult brain is composed largely of non-dividing cells, and 
therefore DNA viruses have become the vehicle of choice for neurobiologists interested in 
somatic gene transfer. By re-expressing an absent protein or by overexpressing a certain 
protein (i.e increasing its concentration), one can unravel its functions and possible process 
that it underlies (Howarth et al., 2010).    
2.2 Tracing 
Detailed knowledge of the complex anatomical interconnections of the central nervous 
system (CNS) plays an important role in the understanding of brain function, both in 
physiological and in pathological conditions. For this, in vivo tracing of neural tracts 
constitutes an important tool.  Some viral vectors systems, especially lentivirus, are largely 
used to this end. The idea is to construct vectors expressing a marker protein, like GFP that 
are anterogradely (from the cell soma to the neurites - see glossary) or retrogradely (from the 
neurites to the cell soma) transported along the neurons (Figure 3). In this manner, one can 
inject an anterograde vector into a certain brain region in order to see where its projections 
are issued. Similarly, using a retrograde vector, one can identify from where come its inputs 
(Figure 4) (Masamizu et al., 2011). 
 
Fig. 3. Transport anterograde and retrograde. The former is from de cell soma to the axon 
terminals. This is also the sense of the nerve impulsions. Conversely, retrograde transport is 
from the axon terminals to the cell soma. Then, if one injects an anterograde vector in a 
certain brain region, we will observe to where it issues its projections. On the other hand, 
injection of a retrograde vector, allows us to know from where come the inputs of the 
injected brain region. 
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Fig. 4. (A) Optical microscopy of an anterograde vector, showing axon projections from the 
prefrontal cortex. (B) Optical microscopy of a retrograde vector, showing cell soma that 
inputs into the prefrontal cortex.  
2.3 Optogenetics 
Optogenetics is a new and promising gene and neuroengineering tool, which allows the 
control of the activity of defined populations of neurons. With this technology, by the 
combination of genetic and optical methods, imaging or control of specific events in target 
cells of living tissues with temporal precision became possible. The optical part consists in 
the use of specific light-sensitive proteins expressed in the neurons of interest. These are 
channel proteins that have either been rendered responsive to light or that are inherently 
light-sensitive, making possible the manipulation, that is, activation or inhibition, of 
neuronal activity.  
The genetic methods concern to the construction of expression cassettes, using cell type 
specific promoters (see glossary). Specifically coupling the DNA sequence of the light-
sensitive protein with a cell-specific promoter, one can drive protein expression in neurons 
defined by a common genetic identity and, possibly, common functional roles. 
Optogenetics has provided a tool that may overcome some of the limitations of traditional 
neuromodulation techniques. Activation or inhibition of specific neuronal populations with 
different wavelengths of light opens up possibilities for modulating neural circuits with 
previously unimagined levels of precision.  
Optogenetics have advanced rapidly since 2005, when it has been demonstrated that 
neurons expressing the ChR2 (channelrhodopsin-2) protein can generate action potentials 
when illuminated by light with a specific wavelength (Boyden et al. 2005). This protein is 
derived from a unicellular alga that was engineered for stable membrane expression into 
mammalian brain. This is a light-sensitive cation channel that triggers depolarizing action 
potentials (see glossary) when exposed to 470 nm blue light. Currently, ChR2 protein 
variants have been generated in order to improve its functionality, especially concerning 
deactivation kinetics and activation lasting. 
Another light-sensitive protein largely used as an optogenetics tool is a bacteria-derived 
chloride pump, called halorhodopsin (NpHR). This protein provokes neuronal activity 
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inhibition, by generating a fast chloride ion influx whereby it leads to membrane 
hyperpolarization (see glossary), when activated by 570 nm yellow light. As for ChR2, more 
efficient variants of NpHR have been generated.    
As ChR2 and NpHR proteins are activated by separate wavelengths of light, activation or 
inhibition of action potential activity in ChR2- and NpHR-expressing cells can be 
independently controlled.  Moreover, co-expression of ChR2 and NpHR within a single 
neuron allows bidirectional control of membrane action potential.   
These light-sensitive proteins, both belonging to the family of opsin genes, can be 
genetically targeted into specific brain cell types using stereotactically injected viral vectors. 
Lentiviral and adeno-associated viral (AAV) vectors are both suitable for such gene transfer. 
Notably, AAV has been considered a safer vector for CNS gene transfer and has been used 
in several clinical trials, because of its innocuous and non-pathogenic features.  
Other expression systems were developed that are more suitable for basic and preclinical 
researches than for clinical trials. This includes generation of transgenic mice expressing 
ChR2 in a subset of neurons. Another approach consists in the use of Cre-recombinase 
knock-in mice (see glossary) injected with Cre-activated AAV vectors encoding opsin genes 
(Henderson et al., 2009; Fiala et al., 2010; Knöpfel et al., 2010; Mancuso et al., 2010; Kravitz & 
Kreitzer, 2011; LaLumière, 2011; Yizhar et al., 2011).    
 
Fig. 5. Sensitive-light proteins and the basis of optogenetics technology. 
These techniques have been used in the analysis of neural circuits, activation of reflexive 
behavior, induction of behavior plasticity, linking cell activity to behavior, among others. As 
an example, using a combination of Cre-inducible ChR2 with parvalbumin-positive 
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interneuron-specific or pyramidal cell-specific Cre driver cell lines, it was identified that 
parvalbumin fast-spiking interneurons have a specific and important role in the generation 
of gamma-oscillations in the barrel cortex and that perceptual decisions and learning can be 
controlled by a subset of excitatory neurons, in mice (Cardin et al. 2009; Sohal et al., 2009).   
Currently, the possible application of optogenetic tools with therapeutic approaches for 
neurological conditions just starts to be considered and investigated. Possible targets would 
be activation and recovery of breathing, suppression of seizure-like activity, amelioration of 
parkinsonian symptoms, recovery of blindness and optical deep brain stimulation. Yet, 
peripheral nervous system targets could also be plausible (Nagel et al., 2005; Gradinaru et 
al., 2009; Adamantidis et al., 2010; Dani et al., 2010; Gradinaru et al., 2010; Zhang et al., 2010; 
Depuy et al., 2011; Kokaia & Sørensen, 2011; Peled, 2011; Tønnesen et al., 2011).   
2.4 Gene therapy 
Gene therapy (GT) constitutes a therapeutic intervention based on modifications of the genetic 
material of target cells, by either correcting genetic defects or overexpressing therapeutically 
useful proteins. Initially designed to definitely correct monogenic disorders such as cystic 
fibrosis, severe combined immunodeficiency or muscular dystrophy, gene therapy has 
evolved into a promising therapeutic modality for a diverse array of diseases. Targets are 
expanding and currently include not only genetic, but also many acquired diseases, such as 
cancer, tissue degeneration or infectious diseases. Over the past years, significant progress was 
made concerning to enabling technologies (see glossary), molecular understanding of several of 
these diseases and manufacturing of vectors. The basic prerequisites to GT success include 
therapeutically suitable genes, appropriate gene delivery systems and proof of safety and 
efficacy. Among them, gene delivery systems constitute a crucial requirement. Depending on 
the duration planned for the treatment, type and location of target cells, and whether they 
undergo division or are quiescent, different vectors may be used, involving non-viral methods, 
non-integrating viral vectors or integrating viral vectors. Advances, especially, in viral vectors 
engineering and improved gene regulatory systems to facilitate and tightly control therapeutic 
gene expression have leading to GT progress (Coura & Nardi, 2008).  
The first gene therapy clinical trial was carried out in 1989, in patients with advanced 
melanoma, using tumor-infiltrating lymphocytes modified by retroviral transduction. In the 
early 90’s, a clinical trial with children with severe combined immunodeficiency (SCID) was 
also performed, by retrovirus transfer of the deaminase adenosine gene to lymphocytes 
isolated from these patients. Since then, more than 5,000 patients have been treated in more 
than 1,000 clinical protocols all over the world (http://www.wiley.co.uk/genetherapy/ 
clinical). Despite the initial enthusiasm, however, the efficacy of gene therapy in clinical trials 
has not been as high as expected; a situation further complicated by ethical and safety concerns 
(Coura & Nardi, 2008). Further studies are being developed to solve these limitations. 
2.4.1 Brain gene therapy 
The advances of modern molecular biology and in vivo gene therapy have challenged 
neuroscientists with the potential prospect of genetically manipulating post-mitotic neurons. 
The ability to alter gene expression in these cells would open the door towards potential 
therapies for several disorders such as Parkinson's disease, Huntington's disease and 
amyotrophic lateral sclerosis. Gene therapy using viral-based vectors has received 
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considerable attention and represents a major focus of ongoing research. Viral vectors using 
several different human viruses such as adeno-associated viruses, herpes viruses and 
lentiviruses are currently being developed for brain gene therapy purposes. Gene therapy 
directed towards neuronal cells however, presents unique problems. These problems 
include the genetic manipulation of post-mitotic (i.e., non-dividing) cells, the ability to 
specifically infect neurons, long-term maintenance of the vector DNA and expression of the 
target gene within the neuronal cells. Herpesviruses, particularly herpes simplex virus type 
1, have unique characteristics of infection, replication and pathogenesis which make them 
potentially ideal candidates for the development of viral vectors capable of altering 
endogenous gene expression or delivery of foreign genes both in vivo and in vitro.  
In the same way, AAV vectors present great potential and appear to be much more 
promising for a wide range of gene therapy approaches. Current studies have been leading 
to great improvements in AAV vector and expression cassette design and novel AAV 
serotypes have been identified, that have improved AAV vectors efficacy (Kaspar et al., 
2002; Coura & Nardi, 2007; McCown, 2011). 
Vectors based on minimal self-inactivating (SIN) and pseudotyping lentiviruses have been 
considered as relevant vector for research and clinical applications. In these vectors, the 
entire coding regions of the virus are removed and provided in trans from separated 
expression cassettes, so that they present less than 1 kb of viral genome and express only the 
transgene cassette. In addition, the use of an envelope from another virus (pseudotyping), 
like the vesicular stomatitis virus (VSV-G), can give vectors broad species and tissue 
tropism. Moreover, innate and adaptive immune responses against these lentiviral vectors 
are not significant. All together, these features are encouraging their use for CNS 
applications (Escors & Breckpot, 2010).   
All these vectors have been largely used in pre-clinical and/or clinical trials. In many 
indications, both AAV and lentiviral vectors are being assessed. This is the case for gene 
therapy approaches in epilepsy, multiple sclerosis, Alzheimer disease, diabetes, Parkinson’s 
disease, chronic pain, lysosomal storage disorders, amyotrophic lateral sclerosis, brain 
ischemia, seizure, Huntington disease, and others. HSV vectors have also been used for 
some of these indications, but currently, they have been frequently applied for gene therapy 
approaches in brain tumors, as is the case for adenovirus vectors as well (Maingay et al., 
2005; Wong et al., 2006; Robinson et al., 2007; Lowery et al., 2009; Shih et al., 2009; Björklund  
et al., 2010; Manfredsson & Mandel, 2010; Eskenazi & Neumaier, 2011; Jacobs & Wang, 2011; 
Van der Perren et al., 2011; Vande Velde et al., 2011; Thaci et al., 2011). 
3. Summary 
Viruses are intracellular parasites with simple DNA or RNA genomes with a unique 
capacity to enter the cell and to replicate their genome. This has given rise to the possibility 
to construct vectors containing the viral envelop and a recombinant genome, so that these 
vectors could be able to deliver genetic material into cells. Viral vectors hold promise for 
basic and clinical research in neurosciences and currently the vehicles of choice for gene 
transfer into the adult mammalian brain. Main viral vectors exploited for use in 
neurobiology are adeno-associated vectors, herpes simplex vectors and lentiviral vectors.  
Each has both advantages and disadvantages depending basically on the subset of target 
cells and the specificities of each research or clinical indication.  
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The spectrum of research and therapeutic applications of viral vectors increase to the extent 
that advances are made in this area. Currently, these applications include functional studies 
by gene expression in vitro and in vivo; neuronal tracing, allowing unraveling anatomical 
neuronal interconnections; neuromodulation, using optogenetic tools and gene therapy.  
Nevertheless, for each approach there are still a lot of technical hurdles to overcome. 
However, advancement in this field will most likely lead to new tools being created with the 
ability to overcome current limitations.  
4. Glossary 
Term Definition
Gene 
expression 
The process of formation of messenger RNA (mRNA) of a DNA template which 
then is translated into the sequence of aminoacids at the ribosome to make proteins. 
Transgene A foreign gene introduced into the cell (for example by a viral vector). 
Transfection 
Process of delivering a foreign gene into the target cell, by a non-viral vector or 
naked DNA.
Transduction Process of delivering a foreign gene into the target cell, by a viral vector. 
Expression 
cassette 
A piece of DNA containing elements (promoter, coding part and polyadenylation 
signal) necessary for expression of a transgene.
Promoter 
Region of DNA that facilitates the transcription of a particular gene. Promoters 
are located near the genes they regulate, on the same strand and typically 
upstream (towards the 5’ region of the sense strand).
Cre  
Cre is a 38 kDa recombinase protein from bacteriophage P1 which mediates 
intramolecular (excisive or inversional) and intermolecular (integrative) site 
specific recombination between loxP sites. A loxP consists of two 13 bp inverted 
repeats separated by an 8 bp asymmetric spacer region. The Cre's DNA excising 
capability can be used to turn on a foreign gene by cutting out an intervening stop 
sequence between the promoter and the coding region of the transgene. 
Gene knockout 
It is a genetic technique in which one of an organism’s gene is made inoperative, 
basically by gene deletion or disruption.
Knock-in 
Genetic engineering method that involves the insertion of a protein coding 
sequence at a particular locus in an organism’s chromosome.
Neurites 
Refers to any projection from the cell body of a neuron. This projection can be 
either an axon or a dendrite.
Depolarization 
Change in a cell's membrane potential, making it more positive or less negative. A 
large enough depolarization may result in an action potential that triggers 
excitation of the neuron activity.
Hyperpolariza- 
tion 
Change in a cell's membrane potential, making it more negative, inhibiting the 
rise of an action potential and, consequently inhibiting neuronal activity. 
Enabling 
technology 
Set of new processes and new techniques that enable the development and 
improvement of existing technologies.
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